Aimovig FDA Approval History
Reviewed by J.Stewart B.Pharm. Last updated on May 18, 2018.
Aimovig (erenumab-aooe) is a calcitonin gene-related peptide (CGRP) receptor antagonist indicated for the preventive treatment of migraine.
Dosage and Administration
- Aimovig is a subcutaneous injection supplied as a 70 mg/mL solution in a single-dose prefilled SureClick® autoinjector or single-dose prefilled syringe.
- The recommended dosage is 70 mg once monthly, although some patients may benefit from a dosage of 140 mg once monthly (administered as two consecutive injections of 70 mg each).
- The needle shield within the white cap of the prefilled autoinjector and the gray needle cap of the prefilled syringe contain dry natural rubber (a derivative of latex), which may cause allergic reactions in individuals sensitive to latex.
- The injection should be administered subcutaneously into the abdomen, thigh, or upper arm.
The most common adverse reactions in Aimovig clinical studies (occurring in at least 3% of treated patients and more often than placebo) are injection site reactions and constipation.
Development Timeline for Aimovig
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.